Mycobacterium tuberculosis (M. tb) can become a long-term infection by evading the host’s immune response. Virulent mycobacterial strains employ various strategies to hijack the host’s immune systems in favor of persistent infection and disease progression. Although the immune evasion mechanisms identified so far are already numerous, they most likely represent only the tip of the iceberg. Identifying fundamental pathogen virulence regulators and investigating the underlying immune mechanisms remain critical in the quest for more effective vaccines and therapeutic targets.
Ubiquitin (Ub) targeting intracellular bacteria is a crucial innate immune mechanism in mammalian cells against intracellular pathogens. Herpesvirus-associated ubiquitin-specific protease (HAUSP USP7) is a deubiquitinase (DUB) that mediates the expression and function of proteins regulating cellular processes and modulating their state of ubiquitination (1, 2). Kim et al., 2022, now add this protease to the list of proteins exploited by M. tb to avoid host immune responses.
M. tb possesses a unique family of proteins, named PE_PGRS. Recently, an increasing number of reports have shown that the mycobacterial PE_PGRS proteins play critical roles in bacterial pathogenesis and immune evasion (3). PE_PGRS38, encoded by Rv2162c in pathogenic mycobacterial species (4), is identified as a potential target for the second-line anti-TB drug, Capreomycin (5). Kim et al., 2022, found that PE_PGRS38 binds to HAUSP and thereby regulates the activity of various proteins through modulation of their state of ubiquitination. The overall downstream effect of PE_PGRS38 interaction with HAUSP increased intracellular survival of the bacteria and downregulated inflammatory cytokine levels.
TNF Receptor Associated Factor 6 (TRAF6) is an intermediate protein in inflammatory-related signaling pathways and the regulation of its cytosolic level is crucial in maintaining cellular homeostasis (6–8). Mycobacterial antigens have been reported to interact with TRAF6 and thus regulate inflammation in the host. HAUSP is a positive regulator of TRAF6 in macrophages, allowing increased stability following lipopolysaccharide treatment. On the other hand, the interaction between HAUSP and PE_PGRS38 promotes the degradation of TRAF6 by inducing ubiquitination, which results in alterations in cytokine levels and increased bacterial persistence as a downstream effect (Kim et al., 2022). Taken together, PE_PGRS38 could be a potential virulence factor for M. tb involved in modulating cytokine production by directly binding to HAUSP via regulation of TRAF6.
A complex cell-wall structure acts as a natural barrier between the slow-growing mycobacterium species and the uptake of antibiotics. The highly branched arabinogalactan (AG), and the characteristic long-chain mycolic acid, forms the mycobacterial cell-wall core (9). EmbA and EmbB are among the key genes involved in AG synthesis (10). The EmbA–EmbB–AcpM2 complex is the target for the anti-TB drug, ethambutol, where over-expression of embA and embB is associated with high-level ethambutol resistance (11–14). Li et al., 2022 showed a reduced level of ethambutol resistance in the EmbA-KD strain, which causes early clearance of M. marinum by the host innate immunity through reprogramming of the oxidative metabolism of macrophages, suggesting potential targets for anti-TB immune intervention.
Foamy macrophages are associated with chronic inflammation in metabolic, infectious, or autoimmune diseases. M. tb-infected foamy macrophages (FMs) represent a hallmark of TB lesions and are characterized by bubble-like lipid bodies in their cytoplasm (15) with morphologic and functional alterations including reduced phagocytic and antimicrobial activity (16). FMs play an important role in the development of active TB diseases and infection dissemination. This is governed via modulating nuclear transcription receptors including the lipid-activated nuclear receptor, such as peroxisome proliferator-activated receptor gamma (PPARgamma) as well as membrane receptors such as CD36, SR-A1, and ABCG1, via enhanced lipid intake and cholesterol efflux (17).
The relative lipid composition of FMs differ in disease contexts, which could be attributed to the expression and function of PPARgamma by regulating intake/efflux. In silicosis, PPARgamma antagonist GW9662 treatment downregulated CD36 expression and inhibited FM formation (18). In alveolar proteinosis, PPARgamma regulates the formation of FM by modulating the expression of ABCG1 (19).
A study by Ye et al., 2022, investigated the molecular mechanisms involved and the role of PPARgamma activation on the expression of lipid metabolism-related molecules. The results showed that reduced PPARgamma expression was accompanied by increased FM formation. Using THP-1 cells, the authors provided evidence that PPARgamma plays an important role in regulating lipid metabolism in TB-related FM formation.
Together, the studies included in this thematic ‘Research Topic’ suggest fundamental mechanisms for how mycobacterial virulence factors circumvent various aspects of the host immune function to promote M. tb pathogenesis. These molecular pathways may represent novel or improved targets for vaccines and/or anti-TB drugs.
Statements
Author contributions
MH designed and prepared the original editorial draft. AM and AS revised the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BhattacharyaSChakrabortyDBasuMGhoshMK. Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases. Signal transduction targeted Ther (2018) 3(1):1–12. doi: 10.1038/s41392-018-0012-y
2
ZhouJWangJChenCYuanHWenXSunH. USP7: Target validation and drug discovery for cancer therapy. Medicinal Chem (2018) 14(1):3–18. doi: 10.2174/1573406413666171020115539
3
De MaioFBerisioRManganelliRDeloguG. PE_PGRS proteins of mycobacterium tuberculosis: A specialized molecular task force at the forefront of host–pathogen interaction. Virulence (2020) 11(1):898–915. doi: 10.1080/21505594.2020.1785815
4
TianCJian-PingX. Roles of PE_PGRS family in mycobacterium tuberculosis pathogenesis and novel measures against tuberculosis. Microbial pathogenesis (2010) 49(6):311–4. doi: 10.1016/j.micpath.2010.07.004
5
ZhengFXieJ. The interaction topology of mycobacterium tuberculosis genes response to capreomycin and novel clues for more drug targets. J Cell Biochem (2011) 112(10):2716–20. doi: 10.1002/jcb.23232
6
WalshMCLeeJChoiY. Tumor necrosis factor receptor-associated factor 6 (TRAF 6) regulation of development, function, and homeostasis of the immune system. Immunol Rev (2015) 266(1):72–92. doi: 10.1111/imr.12302
7
LiJLiuNTangLYanBChenXZhangJet al. The relationship between TRAF6 and tumors. Cancer Cell Int (2020) 20(1):1–12. doi: 10.1186/s12935-020-01517-z
8
YamamotoMGohdaJAkiyamaTInoueJ-I. TNF receptor-associated factor 6 (TRAF6) plays crucial roles in multiple biological systems through polyubiquitination-mediated NF-κB activation. Proc Japan Academy Ser B (2021) 97(4):145–60. doi: 10.2183/pjab.97.009
9
AbrahamsKABesraGS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.. (2016), 145116-133. doi: 10.1017/S0031182016002377
10
PalčekováZAngalaSKBelardinelliJMEskandarianHAJoeMBruntonRet al. Disruption of the SucT acyltransferase in mycobacterium smegmatis abrogates succinylation of cell envelope polysaccharides. J Biol Chem (2019) 294(26):10325–35. doi: 10.1074/jbc.RA119.008585
11
ZhangLZhaoYGaoYWuLGaoRZhangQet al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science (2020) 368(6496):1211–9. doi: 10.1126/science.aba9102
12
XiangXGongZDengWSunQXieJ. Mycobacterial ethambutol responsive genes and implications in antibiotics resistance. J Drug Targeting (2021) 29(3):284–93. doi: 10.1080/1061186X.2020.1853733
13
ZhangLZhaoYGaoRLiJYangXGaoYet al. Cryo-EM snapshots of mycobacterial arabinosyltransferase complex EmbB2-AcpM2. Protein Cell (2020) 11(7):505–17. doi: 10.1007/s13238-020-00726-6
14
BelangerABesraGFordMMikusováKBelisleJTBrennanPJ. Inamine JM the embAB genes of mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA (1996) 93(21):11919–24. doi: 10.1073/pnas.93.21.11919
15
ShimDKimHShinSJ. Mycobacterium tuberculosis infection-driven foamy macrophages and their implications in tuberculosis control as targets for host-directed therapy. Front Immunol (2020) 11:910. doi: 10.3389/fimmu.2020.00910
16
AgarwalPCombesTWShojaee-MoradieFFieldingBGordonSMizrahiVet al. Foam cells control mycobacterium tuberculosis infection. Front Microbiol (2020) 11:1394. doi: 10.3389/fmicb.2020.01394
17
WagerCMLArnettESchlesingerLS. Mycobacterium tuberculosis and macrophage nuclear receptors: What we do and don’t know. Tuberculosis (2019) 116:S98–S106. doi: 10.1016/j.tube.2019.04.016
18
HouXSummerRChenZTianYMaJCuiJet al. Lipid uptake by alveolar macrophages drives fibrotic responses to silica dust. Sci Rep (2019) 9(1):1–13. doi: 10.1038/s41598-018-36875-2
19
MalurABakerADMccoyAJWellsGBarnaBPKavuruMSet al. Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. Am J Physiology-Lung Cell Mol Physiol (2011) 300(1):L73–80. doi: 10.1152/ajplung.00128.2010
Summary
Keywords
immune evasion, PPAR γ, foamy macrophage, arabinogalactan, innate immunity, M.tb
Citation
Habtamu M, Miheret A and Spurkland A (2022) Editorial: Host immune evasion by Mycobacterium tuberculosis: Current updates. Front. Immunol. 13:1102415. doi: 10.3389/fimmu.2022.1102415
Received
18 November 2022
Accepted
05 December 2022
Published
13 December 2022
Volume
13 - 2022
Edited and reviewed by
Ian Marriott, University of North Carolina at Charlotte, United States
Updates
Copyright
© 2022 Habtamu, Miheret and Spurkland.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Meseret Habtamu, meseret.habtamu@ahri.gov.et
This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.